查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004923

核醫放射性同位素市場：2026-2032年全球市場預測（依同位素功能、給藥途徑、生產技術、最終用戶和疾病領域分類）

Nuclear Medicine Radioisotopes Market by Isotope Function, Mode Of Administration, Production Technology, End User, Disease Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，核醫放射性同位素市場價值將達到 68.9 億美元，到 2026 年將成長至 75.5 億美元，到 2032 年將達到 134.4 億美元，複合年成長率為 9.99%。

主要市場統計數據
基準年 2025 68.9億美元
預計年份：2026年 75.5億美元
預測年份 2032 134.4億美元
複合年成長率 (%) 9.99%

這是一本權威的入門書籍，說明了臨床創新、生產技術和監管變化如何重塑核醫放射性同位素生態系統。

核醫學放射性同位素產業目前正經歷重大變革時期，其驅動力來自臨床創新、生產技術的轉變以及監管重點的不斷變化。該行業傳統上專注於影像學以及發生器生產的少量同位素，如今已擴展到精準醫療、一體化診療路徑以及分散式生產模式，這些都對傳統的供應鏈提出了挑戰。因此，醫療系統、製造商和監管相關人員都面臨新的技術和商業性現實，需要採取明智且具有策略性的應對措施。

簡要反思臨床實踐、生產方法和監管期望的系統性變革，這些變革正在重新定義該領域。

過去幾年，核子醫學領域放射性同位素的臨床應用、供應鏈和法規結構都發生了變革性變化。在臨床上，將診斷影像和標靶放射治療緊密結合的「治療診斷學」模式正迅速發展，改變標準的治療路徑，並催生了對特定放射性同位素和標記化合物的新需求模式。同時，分子標靶和放射化學領域的進展正在擴大多種藥物的治療指數，從而促進更廣泛的臨床評估和應用。

重點分析美國在 2025 年推出的關稅措施如何重塑採購、供應鏈戰略和區域製造業優先事項。

2025年，美國關稅政策的變化進一步擾亂了依賴跨境供應放射性同位素前體、發生器、合成模組和專用耗材的相關人員。這種累積影響體現在籌資策略、供應鏈結構和成本結構的各個方面。依賴進口的企業被迫重新評估其供應商，許多企業正在加快本地製造計劃或在未受關稅調整影響的市場中尋找替代供應商。

詳細的分割分析表明，診斷用 PET 和 SPECT 顯像劑和治療方式各自需要不同的技術、臨床和商業性策略。

細分分析揭示了診斷和治療性放射性藥物在技術、臨床和商業性的顯著趨勢。診斷性放射性藥物分為PET和SPECT兩大類。在PET放射性藥物中，F-18 FDG已成為腫瘤學中常用的常規影像工具，而F-18 PSMA由於其優於其他PSMA示蹤劑的特異性和易用性，在前列腺癌分期和復發檢測中日益受到重視。 SPECT放射性藥物在γ射線發射同位素仍然經濟有效且廣泛可用的領域繼續發揮廣泛的臨床作用。治療性放射性藥物包括針對生長抑制素受體的同位素和配體依賴性胜肽受體放射性核素療法（對神經內分泌腫瘤具有良好的劑量分佈特性）、將高劑量BETA射線發射藥物直接輸送到肝臟腫瘤的放射性栓塞療法，以及將單株抗體和細胞毒性同位素聯合用於標靶全身性治療的放射免疫療法。

主要區域展望顯示美洲、歐洲、中東和非洲以及亞太地區在採用率、製造能力和法規環境的差異。

區域差異導致美洲、歐洲、中東和非洲以及亞太地區在PET示蹤劑的應用曲線、監管方式和製造地存在顯著差異。在美洲，一體化的醫療網路和先進的影像基礎設施支援新型PET示蹤劑和診療一體化製劑的快速臨床應用，同時相關政策和報銷框架也在不斷發展，以適應高價值放射療法的需求。相較之下，歐洲、中東和非洲地區的情況則較為複雜，既有成熟的高效醫療中心，也有面臨物流和監管障礙的地區。泛歐監管協調工作和各國為確保同位素供應而採取的措施正在影響製造商和臨床機構的策略規劃。

產業領導者正在實施策略性企業應對措施和夥伴關係模式，以確保供應鏈安全、加速臨床部署並透過自身能力實現差異化。

放射性同位素領域的企業策略如今強調整合價值鏈、策略夥伴關係和能力主導的差異化。各公司優先投資迴旋加速器網路和自動化合成平台等生產技術，同時拓展其放射化學和臨床開發能力。隨著各公司致力於降低供應風險、縮短臨床試驗週期並累積證據以支持醫保報銷和更廣泛的臨床應用，同位素生產商、合約研發生產機構 (CDMO) 和臨床服務提供者之間的合作日益普遍。

產業領導者可以實施的可操作建議，以加強供應鏈韌性、加速臨床檢驗並有效實現治療診斷學創新商業化。

產業領導者應推動一系列合作舉措，以增強供應鏈韌性，加速臨床檢驗，並建構一個能夠從新興的治療診斷學模式中獲取長期價值的系統。首先，應優先投資區域生產能力和檢驗的替代生產路線，以減少對單一來源進口的依賴。其次，應促進放射化學家、醫學物理學家和臨床試驗負責人之間的跨學科合作，以產生可靠的臨床證據，並完善劑量和安全通訊協定，從而改善患者療效並增強支付方的信心。

採用嚴謹的混合方法研究途徑，結合專家的初步訪談、技術文獻的整合以及製造和監管流程的梳理。

本分析所依據的研究採用了一種混合方法，旨在整合技術、臨床和商業性觀點。研究人員透過對臨床醫生、放射藥劑師、生產專家和監管顧問進行結構化訪談，收集了主要的定性數據，以了解實際操作情況、未滿足的需求以及推廣應用的障礙。這些發現與二手技術文獻、同行評審的臨床研究、監管指導文件以及公開的臨床試驗註冊資訊進行了交叉比對，從而全面了解了科學和臨床趨勢。

一項決定性的整合，突顯了臨床創新、製造現代化和協作策略之間為未來成功而進行的關鍵相互作用。

總之，核醫放射性同位素正處於臨床創新、生產現代化和監管完善的快速發展交會點。治療診斷學的興起、迴旋加速器能力的提升以及對更具韌性的供應鏈的需求，正在改變放射性藥物的研發、生產和交付方式。醫療系統和生產商若能將自身的技術能力與臨床項目的設計以及積極的監管互動相結合，將更有利於把科學進步轉化為更優質的患者照護。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：核子醫學放射性同位素市場－依同位素功能分類

  • 診斷同位素
    • 用於SPECT的同位素
      • Technetium-99m (Tc-99m)
      • 碘-123 (I-123)
      • 鉈-201 (Tl-201)
      • 鎵-67（Ga-67）
      • 銦-111 (In-111)
    • 用於PET的同位素
      • 氟-18 (F-18)
      • 碳-11 (C-11)
      • 氮-13 (N-13)
      • 氧-15（O-15）
      • 銣-82 (Rb-82)
      • 銅-64 (Cu-64)
  • 治療性同位素
    • BETA射線放射體
    • α粒子發射材料
    • 俄歇電子發射器
    • 用於近距離治療的同位素

第9章：依給藥方式分類的核醫學放射性同位素市場分佈

  • 靜脈注射
  • 口服

第10章 核醫放射性同位素市場（依生產技術分類）

  • 由核子反應爐製造
  • 採用迴旋加速器法製造
  • 發電機
  • 利用直線加速器進行製造

第11章：核醫放射性同位素市場：依最終用戶分類

  • 學術和研究機構
  • 診斷影像中心
  • 醫院
  • 製藥和生物技術公司

第12章 按疾病領域分類的核子醫學放射性同位素市場

  • 腫瘤學
  • 循環系統
  • 神經病學
  • 內分泌學
  • 肺科
  • 腎臟病學
  • 胃腸病學
  • 感染疾病和炎症

第13章：核醫放射性同位素市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：核醫放射性同位素市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：核醫放射性同位素市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國核子醫學放射性同位素市場

第17章 中國核醫放射性同位素市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • BWX Technologies Inc
  • Cardinal Health
  • China Isotope & Radiation Corporation
  • Curium Pharma
  • Eckert & Ziegler AG
  • GE HealthCare Technologies Inc
  • Ionetix Corporation
  • IRE ELiT
  • ISOFLEX USA
  • ITM Isotope Technologies Munich SE
  • Life Molecular Imaging
  • NECSA Ltd
  • NorthStar Medical Radioisotopes LLC
  • NTP Radioisotopes SOC Ltd
  • Nusano
  • Orano Med
  • SOFIE Biosciences Inc
  • Telix Pharmaceuticals Ltd
Product Code: MRR-742BD51821D7

The Nuclear Medicine Radioisotopes Market was valued at USD 6.89 billion in 2025 and is projected to grow to USD 7.55 billion in 2026, with a CAGR of 9.99%, reaching USD 13.44 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 6.89 billion
Estimated Year [2026] USD 7.55 billion
Forecast Year [2032] USD 13.44 billion
CAGR (%) 9.99%

An authoritative introduction explaining how clinical innovation, production technology, and regulatory shifts are reshaping nuclear medicine radioisotope ecosystems

The landscape of nuclear medicine radioisotopes is undergoing a period of substantive change driven by converging clinical innovations, shifts in production technology, and evolving regulatory priorities. Historically centered on diagnostic imaging and a small set of generator-produced isotopes, the field now spans precision therapeutics, integrated diagnostic-therapeutic pathways, and more distributed production models that challenge legacy supply chains. As a result, stakeholders across healthcare systems, manufacturers, and regulators are confronting new technical and commercial realities that require informed strategic responses.

In clinical settings, the expansion of theranostics and targeted radionuclide therapies has redefined disease management for oncology and other specialties, increasing demand for reliable isotopic supply, specialized radiochemistry capabilities, and robust logistics. Concurrently, manufacturing innovations such as expanded cyclotron deployment and alternative Mo-99/Tc-99m production pathways are emerging to mitigate historical bottlenecks. Taken together, these forces are reshaping investment priorities and partnership structures. Therefore, an introduction to this domain must emphasize both the technical specifics of isotope production and the system-level implications for clinical adoption, reimbursement, and cross-industry collaboration.

A concise examination of the systemic transformations in clinical practice, production methods, and regulatory expectations that are redefining the sector

The past several years have revealed transformative shifts that are redefining the nuclear medicine radioisotopes landscape across clinical practice, supply chains, and regulatory frameworks. Clinically, the rapid uptake of theranostic paradigms-where diagnostic imaging tightly couples with targeted radiotherapeutics-has changed standard care pathways and created new demand profiles for specific radioisotopes and labeled compounds. Concurrent advances in molecular targeting and radiochemistry have expanded the therapeutic index for several agents, prompting broader clinical evaluation and adoption.

On the production side, there has been a marked move toward decentralization with greater investment in hospital-based and regional cyclotron capacity, as well as interest in alternative generator and reactor-independent production techniques. These developments are complemented by improvements in automation for synthesis and quality control, which streamline operations and reduce exposure risks. From a regulatory perspective, agencies are refining guidance to accommodate novel radiopharmaceutical manufacturing controls, aseptic processing innovations, and accelerated clinical pathways for high-need indications. Together, these shifts are creating a more resilient yet complex ecosystem that rewards integrated technical capability and agile regulatory engagement.

A focused analysis of how United States tariff measures introduced in 2025 are reshaping procurement, supply chain strategy, and regional manufacturing priorities

In 2025, tariff policy changes instituted by the United States introduced another vector of disruption for stakeholders who depend on cross-border supply of radioisotope precursors, generators, synthesis modules, and specialized consumables. The cumulative impacts are observable across procurement strategies, supply chain architecture, and cost structures. Import-dependent organizations have been prompted to reassess sourcing, with many accelerating local manufacturing projects or seeking alternative suppliers in markets unaffected by tariff adjustments.

Beyond procurement, tariffs have influenced contractual negotiations, inventory management practices, and long-term capital planning. Firms that previously relied on low-cost foreign components are now evaluating vertical integration or strategic partnerships to internalize critical capabilities. At the same time, regulatory and customs complexities have created operational friction that can extend lead times for clinical programs and manufacturing scale-up. As a consequence, industry players are prioritizing supply chain mapping, supplier qualification diversification, and investment in regionalized capacity to mitigate tariff-driven exposure and preserve continuity of care.

Granular segmentation insights revealing how diagnostic PET and SPECT agents and therapeutic modalities each demand distinct technical, clinical, and commercial strategies

Segmentation analysis reveals distinct technical, clinical, and commercial dynamics across diagnostic and therapeutic radiopharmaceuticals. Diagnostic agents split into PET and SPECT categories, with PET agents like F-18 FDG established as routine oncologic imaging tools and F-18 PSMA gaining prominence for prostate cancer staging and recurrence detection because of its superior specificity and logistical handling compared with some alternative PSMA tracers. SPECT agents continue to serve widespread clinical roles where gamma-emitting isotopes remain cost-effective and widely available. Therapeutic agents encompass peptide receptor radionuclide therapy, which leverages somatostatin receptor targeting for neuroendocrine tumors and depends on isotopes and ligands with favorable dosimetry profiles; radioembolization approaches that deliver high-dose beta emitters directly to hepatic tumors; and radioimmunotherapy strategies that combine monoclonal antibodies with cytotoxic isotopes for targeted systemic treatment.

These distinctions carry operational implications for manufacturers and providers. PET workflows require robust radiochemistry, rapid distribution, and regulatory compliance for short-lived isotopes, while therapeutic modalities demand specialized dosimetry, patient selection protocols, and multidisciplinary clinical teams. Consequently, organizations involved in radiopharmaceutical development must align laboratory capabilities, distribution networks, and clinical partnerships to address the unique requirements of each segment and to translate scientific advances into meaningful patient outcomes.

Key regional perspectives showing how adoption, manufacturing capacity, and regulatory environments vary across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Geographic variation drives meaningful differences in adoption curves, regulatory approaches, and manufacturing footprints across the Americas, Europe, Middle East & Africa, and Asia-Pacific regions. In the Americas, integrated healthcare networks and advanced imaging infrastructure support rapid clinical adoption of novel PET tracers and theranostic agents, while policy and reimbursement frameworks are evolving to accommodate high-value radiotherapeutics. By contrast, Europe, the Middle East & Africa present a heterogeneous landscape where well-established centers of excellence coexist with regions that face logistical and regulatory hurdles; pan-European regulatory harmonization efforts and national initiatives to secure isotope supply influence strategic planning for producers and clinical sites.

In the Asia-Pacific region, rapid investment in cyclotron capacity, growing clinical trial activity, and increasing domestic manufacturing capabilities are notable trends. Several markets in the region are focusing on expanding local production to reduce import dependency and to address rising clinical demand. Across all regions, differences in reimbursement models, hospital infrastructure, and regulatory timelines necessitate tailored commercialization strategies and local partnerships to achieve sustainable access and scale.

Strategic corporate responses and partnership models that industry leaders are deploying to secure supply chains, accelerate clinical adoption, and differentiate through capabilities

Corporate strategies in the radioisotope domain now emphasize integrated value chains, strategic partnerships, and capability-led differentiation. Firms are prioritizing investments in production technologies, such as cyclotron networks and automated synthesis platforms, while also expanding capabilities in radiochemistry and clinical development. Collaboration between isotope producers, contract development and manufacturing organizations, and clinical providers is increasingly prevalent as organizations seek to de-risk supply, accelerate time to clinic, and build evidence that supports reimbursement and broader clinical adoption.

In addition, companies are diversifying route-to-market approaches by licensing proprietary ligands, forming co-development agreements for theranostic pairs, and pursuing regional manufacturing alliances. Intellectual property management, quality systems harmonization, and regulatory engagement remain central to competitive positioning. Collectively, these strategies reflect a shift from single-product development toward end-to-end solutions that marry isotope supply security with clinical utility and commercial scalability.

Actionable recommendations that industry leaders can implement to strengthen supply resilience, accelerate clinical validation, and commercialize theranostic innovations effectively

Industry leaders should pursue a coordinated set of actions that strengthen supply resilience, accelerate clinical validation, and position organizations to capture long-term value from emerging theranostic paradigms. First, prioritize investment in regional production capacity and validated alternative production pathways to reduce dependency on single-source imports. Second, cultivate multidisciplinary collaborations between radiochemists, medical physicists, and clinical trialists to generate robust clinical evidence and to refine dosing and safety protocols that improve patient outcomes and payer confidence.

Furthermore, organizations should engage proactively with regulators to shape pragmatic pathways for quality assurance, sterility testing, and lot release that reflect the technical realities of short-lived isotopes. Operationally, integrating automation and digital quality controls can reduce turnaround times and enhance reproducibility. Finally, commercial strategies must focus on building payer relationships and demonstrating real-world value through outcomes and health economic evidence, while also developing flexible distribution and inventory models that accommodate the logistical constraints of radiopharmaceuticals.

A rigorous mixed-methods research approach integrating primary expert interviews, technical literature synthesis, and production and regulatory process mapping

The research underpinning this analysis employed a mixed-methods approach designed to integrate technical, clinical, and commercial perspectives. Primary qualitative data were collected through structured interviews with clinicians, radiopharmacists, manufacturing specialists, and regulatory advisors to capture operational realities, unmet needs, and adoption barriers. These insights were triangulated with secondary technical literature, peer-reviewed clinical studies, regulatory guidance documents, and publicly available clinical trial registries to ensure a comprehensive understanding of scientific and clinical trends.

Analytical steps included a systematic mapping of production technologies, a review of manufacturing process controls relevant to radiopharmaceuticals, and an assessment of logistics and cold-chain considerations specific to short-lived isotopes. The methodology emphasized reproducibility by documenting data sources, interview protocols, and analytical assumptions, and by conducting sensitivity checks on qualitative findings. Where applicable, patent landscapes and regulatory filings were examined to validate strategic positioning and to identify potential technology inflection points.

A conclusive synthesis emphasizing the critical interplay of clinical innovation, production modernization, and collaborative strategies for future success

In summary, nuclear medicine radioisotopes occupy a fast-evolving junction of clinical innovation, manufacturing modernization, and regulatory refinement. The rise of theranostics, expansion of cyclotron capacity, and the need for more resilient supply chains are collectively altering how radiopharmaceuticals are developed, produced, and delivered. Healthcare systems and manufacturers that align technical capabilities with clinical program design and proactive regulatory engagement will be best positioned to translate scientific advances into improved patient care.

Moving forward, success will depend on cross-sector collaboration, transparent supply chain strategies, and evidence generation that demonstrates clinical and economic value. By embracing integrated approaches that combine secure isotope production, automated manufacturing processes, and targeted clinical development, stakeholders can mitigate operational risk while accelerating adoption of next-generation diagnostic and therapeutic radiopharmaceuticals.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Nuclear Medicine Radioisotopes Market, by Isotope Function

  • 8.1. Diagnostic Isotopes
    • 8.1.1. SPECT Isotopes
      • 8.1.1.1. Technetium-99m (Tc-99m)
      • 8.1.1.2. Iodine-123 (I-123)
      • 8.1.1.3. Thallium-201 (Tl-201)
      • 8.1.1.4. Gallium-67 (Ga-67)
      • 8.1.1.5. Indium-111 (In-111)
    • 8.1.2. PET Isotopes
      • 8.1.2.1. Fluorine-18 (F-18)
      • 8.1.2.2. Carbon-11 (C-11)
      • 8.1.2.3. Nitrogen-13 (N-13)
      • 8.1.2.4. Oxygen-15 (O-15)
      • 8.1.2.5. Rubidium-82 (Rb-82)
      • 8.1.2.6. Copper-64 (Cu-64)
  • 8.2. Therapeutic Isotopes
    • 8.2.1. Beta Emitters
    • 8.2.2. Alpha Emitters
    • 8.2.3. Auger Electron Emitters
    • 8.2.4. Brachytherapy Isotopes

9. Nuclear Medicine Radioisotopes Market, by Mode Of Administration

  • 9.1. Intravenous Injection
  • 9.2. Oral Ingestion

10. Nuclear Medicine Radioisotopes Market, by Production Technology

  • 10.1. Nuclear Reactor Production
  • 10.2. Cyclotron Production
  • 10.3. Generator Systems
  • 10.4. Linear Accelerator Production

11. Nuclear Medicine Radioisotopes Market, by End User

  • 11.1. Academic & Research Institutes
  • 11.2. Diagnostic Imaging Centers
  • 11.3. Hospitals
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Nuclear Medicine Radioisotopes Market, by Disease Area

  • 12.1. Oncology
  • 12.2. Cardiology
  • 12.3. Neurology
  • 12.4. Endocrinology
  • 12.5. Pulmonology
  • 12.6. Nephrology
  • 12.7. Gastroenterology
  • 12.8. Infection And Inflammation

13. Nuclear Medicine Radioisotopes Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Nuclear Medicine Radioisotopes Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Nuclear Medicine Radioisotopes Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Nuclear Medicine Radioisotopes Market

17. China Nuclear Medicine Radioisotopes Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. BWX Technologies Inc
  • 18.6. Cardinal Health
  • 18.7. China Isotope & Radiation Corporation
  • 18.8. Curium Pharma
  • 18.9. Eckert & Ziegler AG
  • 18.10. GE HealthCare Technologies Inc
  • 18.11. Ionetix Corporation
  • 18.12. IRE ELiT
  • 18.13. ISOFLEX USA
  • 18.14. ITM Isotope Technologies Munich SE
  • 18.15. Life Molecular Imaging
  • 18.16. NECSA Ltd
  • 18.17. NorthStar Medical Radioisotopes LLC
  • 18.18. NTP Radioisotopes SOC Ltd
  • 18.19. Nusano
  • 18.20. Orano Med
  • 18.21. SOFIE Biosciences Inc
  • 18.22. Telix Pharmaceuticals Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY TECHNETIUM-99M (TC-99M), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY TECHNETIUM-99M (TC-99M), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY TECHNETIUM-99M (TC-99M), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY IODINE-123 (I-123), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY IODINE-123 (I-123), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY IODINE-123 (I-123), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THALLIUM-201 (TL-201), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THALLIUM-201 (TL-201), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THALLIUM-201 (TL-201), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GALLIUM-67 (GA-67), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GALLIUM-67 (GA-67), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GALLIUM-67 (GA-67), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INDIUM-111 (IN-111), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INDIUM-111 (IN-111), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INDIUM-111 (IN-111), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY FLUORINE-18 (F-18), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY FLUORINE-18 (F-18), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY FLUORINE-18 (F-18), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARBON-11 (C-11), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARBON-11 (C-11), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARBON-11 (C-11), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NITROGEN-13 (N-13), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NITROGEN-13 (N-13), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NITROGEN-13 (N-13), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY OXYGEN-15 (O-15), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY OXYGEN-15 (O-15), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY OXYGEN-15 (O-15), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RUBIDIUM-82 (RB-82), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RUBIDIUM-82 (RB-82), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY RUBIDIUM-82 (RB-82), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COPPER-64 (CU-64), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COPPER-64 (CU-64), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COPPER-64 (CU-64), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BETA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BETA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BETA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ALPHA EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ALPHA EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ALPHA EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY AUGER ELECTRON EMITTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY AUGER ELECTRON EMITTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY AUGER ELECTRON EMITTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY BRACHYTHERAPY ISOTOPES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ORAL INGESTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ORAL INGESTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ORAL INGESTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NUCLEAR REACTOR PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NUCLEAR REACTOR PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NUCLEAR REACTOR PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CYCLOTRON PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CYCLOTRON PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CYCLOTRON PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GENERATOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GENERATOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GENERATOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY LINEAR ACCELERATOR PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY LINEAR ACCELERATOR PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY LINEAR ACCELERATOR PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PULMONOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PULMONOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PULMONOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEPHROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEPHROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY NEPHROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GASTROENTEROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GASTROENTEROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INFECTION AND INFLAMMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INFECTION AND INFLAMMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY INFECTION AND INFLAMMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 179. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 180. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 191. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. AFRICA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 214. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 216. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 218. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 219. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 221. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. GCC NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 244. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 247. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 248. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 249. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 252. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. G7 NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 254. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 257. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 258. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 259. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 260. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY ISOTOPE FUNCTION, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DIAGNOSTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY SPECT ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PET ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY THERAPEUTIC ISOTOPES, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY PRODUCTION TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA NUCLEAR MEDICINE RADIOISOTOPES MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)